XLON
AREC
Market cap25mUSD
Jul 22, Last price
51.50GBP
1D
1.02%
1Q
30.26%
IPO
-79.55%
Name
Arecor Therapeutics PLC
Chart & Performance
Profile
Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑05 | 2018‑05 | 2017‑05 | |
Income | ||||||||
Revenues | 4,573 90.30% | 2,403 107.51% | ||||||
Cost of revenue | 14,890 | 14,506 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (10,317) | (12,103) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | (347) | (1,282) | ||||||
Tax Rate | ||||||||
NOPAT | (9,970) | (10,821) | ||||||
Net income | (8,554) -7.62% | (9,260) 50.11% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 6,000 | |||||||
BB yield | -8.64% | |||||||
Debt | ||||||||
Debt current | 118 | 202 | ||||||
Long-term debt | 558 | 374 | ||||||
Deferred revenue | (496) | |||||||
Other long-term liabilities | 28 | 496 | ||||||
Net debt | (6,153) | (12,278) | ||||||
Cash flow | ||||||||
Cash from operating activities | (5,841) | (10,780) | ||||||
CAPEX | (151) | (345) | ||||||
Cash from investing activities | 6,520 | (7,993) | ||||||
Cash from financing activities | (180) | 5,160 | ||||||
FCF | (8,821) | (12,418) | ||||||
Balance | ||||||||
Cash | 6,752 | 12,806 | ||||||
Long term investments | 77 | 48 | ||||||
Excess cash | 6,600 | 12,734 | ||||||
Stockholders' equity | (19,449) | (13,535) | ||||||
Invested Capital | 29,342 | 31,158 | ||||||
ROIC | ||||||||
ROCE | ||||||||
EV | ||||||||
Common stock shares outstanding | 30,623 | 28,936 | ||||||
Price | 1.83 -23.96% | 2.40 -40.00% | ||||||
Market cap | 55,886 -19.53% | 69,447 -24.62% | ||||||
EV | 49,733 | 57,169 | ||||||
EBITDA | (9,821) | (11,762) | ||||||
EV/EBITDA | ||||||||
Interest | 15 | 26 | ||||||
Interest/NOPBT |